Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Oludamilola A. Olajide"'
Autor:
Zev M. Nakamura, Allison M. Deal, Eliza M. Park, Kate E. Stanton, Yesy E. Lopez, Laura J. Quillen, Erin O’Hare Kelly, Hillary M. Heiling, Kirsten A. Nyrop, Emily M. Ray, E. Claire Dees, Katherine E. Reeder‐Hayes, Trevor A. Jolly, Lisa A. Carey, Yara Abdou, Oludamilola A. Olajide, Julia K. Rauch, Ranjit Joseph, Anureet Copeland, Megan A. McNamara, Tim A. Ahles, Hyman B. Muss
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8172-8183 (2023)
Abstract Background Cognitive difficulties have been described after chemotherapy for breast cancer, but there is no standard of care to improve cognitive outcomes in these patients. This trial examined the feasibility, tolerability, acceptability, a
Externí odkaz:
https://doaj.org/article/d2562d0fa30245228e0ed1a363d25b5d
Autor:
Zev Nakamura, Allison Mary Deal, Eliza Myung Park, Kate Stanton, Yesy Lopez, Laura J. Quillen, Erin O'Hare Kelly, Hillary M Heiling, Kirsten A. Nyrop, Emily Miller Ray, Elizabeth Claire Dees, Katherine Elizabeth Reeder-Hayes, Trevor Augustus Jolly, Lisa A. Carey, Yara Abdou, Oludamilola A. Olajide, Megan Ann McNamara, Tim Ahles, Hyman B. Muss
Publikováno v:
Journal of Clinical Oncology. 40:12109-12109
12109 Background: Up to 75% of patients with breast cancer report cognitive decline following chemotherapy. There is no standard of care prevention or treatment of cognitive problems in these patients. This trial (NCT04033419) examines the feasibilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::819a549acd4d233f7e61244c87774576
https://doi.org/10.1200/jco.2022.40.16_suppl.12109
https://doi.org/10.1200/jco.2022.40.16_suppl.12109